KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Accounts Payables (2016 - 2025)

Gsk (GSK) has 8 years of Accounts Payables data on record, last reported at $19.7 billion in Q4 2024.

  • For Q4 2024, Accounts Payables changed 0.09% year-over-year to $19.7 billion; the TTM value through Dec 2024 reached $19.7 billion, changed 0.09%, while the annual FY2024 figure was $19.6 billion, 0.53% down from the prior year.
  • Accounts Payables reached $19.7 billion in Q4 2024 per GSK's latest filing, roughly flat from $19.7 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $23.7 billion in Q4 2021 and bottomed at $19.1 billion in Q4 2022.
  • Average Accounts Payables over 4 years is $20.5 billion, with a median of $19.7 billion recorded in 2024.
  • Peak YoY movement for Accounts Payables: fell 19.39% in 2022, then increased 3.09% in 2023.
  • A 4-year view of Accounts Payables shows it stood at $23.7 billion in 2021, then fell by 19.39% to $19.1 billion in 2022, then rose by 3.09% to $19.7 billion in 2023, then rose by 0.09% to $19.7 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $19.7 billion in Q4 2024, $19.7 billion in Q4 2023, and $19.1 billion in Q4 2022.